Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 2:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,143 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Autologous Transplantation Clear all
Completed Phase 3 Interventional Results available

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT03391466
View directory record Official record
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
Axicabtagene Ciloleucel, Platinum-containing Salvage Chemotherapy, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
30
States / cities
Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 7, 2026, 2:42 PM EDT
Terminated Phase 1 Interventional Results available

Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation

NCT01251952
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Denileukin Diftitox (Ontak)
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 7, 2026, 2:42 PM EDT
Completed Phase 2 Interventional

Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia

NCT00005948
View directory record Official record
Conditions
Leukemia
Interventions
aldesleukin, recombinant interferon alfa, sargramostim, busulfan, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
2
States / cities
Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced Sep 7, 2026, 2:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

NCT00964821
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 7, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)

NCT00684021
View directory record Official record
Conditions
Left Ventricular Dysfunction
Interventions
Adult stem cells, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Sep 7, 2026, 2:42 PM EDT
Completed Phase 2 Interventional

Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation

NCT01660633
View directory record Official record
Conditions
Multiple Myeloma
Interventions
High-Dose Melphalan HCL for Injection (Propylene Glycol-Free), Autologous Transplantation
Drug · Other
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
Up to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
6
States / cities
Chicago, Illinois • Fairway, Kansas • Worcester, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 7, 2026, 2:42 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Congenital Pseudarthrosis of the Tibia.

NCT07112443
View directory record Official record
Conditions
Congenital Pseudarthrosis of Tibia
Interventions
NVD003, Iliac Crest Bone Graft
Biological · Procedure
Lead sponsor
Novadip Biosciences
Industry
Eligibility
Up to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Loma Linda, California • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 7, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

NCT01270724
View directory record Official record
Conditions
CNS Germ Cell Tumor
Interventions
Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 7, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00096382
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, filgrastim, therapeutic tumor infiltrating lymphocytes, cyclophosphamide, fludarabine phosphate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Sep 7, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma

NCT01045460
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Activated marrow infiltrating lymphocytes, Allogeneic Myeloma Vaccine, Cyclophosphamide, Filgrastim, Leukapheresis, Melphalan, Autologous stem cell transplant
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Sep 7, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients

NCT00103610
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Granulocyte colony-stimulating factor plus plerixafor, Granulocyte colony-stimulating factor plus placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 78 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
31
States / cities
Phoenix, Arizona • Duarte, California • Denver, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Sep 7, 2026, 2:42 PM EDT
Active, not recruiting Phase 2 Interventional

Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT02420860
View directory record Official record
Conditions
Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
Interventions
Elotuzumab, Lenalidomide, Questionnaire Administration
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 7, 2026, 2:42 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Multiple Myeloma

NCT00019097
View directory record Official record
Conditions
Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
Interventions
autologous tumor cell vaccine, keyhole limpet hemocyanin, melphalan, sargramostim
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Timeline
1995 – 2007
U.S. locations
3
States / cities
Little Rock, Arkansas • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 7, 2026, 2:42 PM EDT
Terminated Phase 2 Interventional

Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma

NCT00005987
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
carmustine, cyclophosphamide, dexamethasone, etoposide, filgrastim, mitoxantrone hydrochloride, recombinant interferon alfa, sargramostim, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 7, 2026, 2:42 PM EDT
Completed Phase 2 Interventional

Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

NCT00006890
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
prednisone, thalidomide
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
16 Years to 120 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Sep 7, 2026, 2:42 PM EDT
Completed Phase 1 Interventional

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

NCT02655458
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, autologous PBMC reconstitution, ASCT
Drug · Other
Lead sponsor
Hearn Jay Cho
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 7, 2026, 2:42 PM EDT
Completed Not applicable Interventional

BFR Therapy for Post-Op Rehab of ACL Reconstruction With Quadriceps Tendon Autograft

NCT04519801
View directory record Official record
Conditions
ACL Injury
Interventions
Blood Flow Restriction (BFR) therapy, Standard REHAB
Other
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
15 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 7, 2026, 2:42 PM EDT
Completed Phase 1 Interventional

Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL

NCT00477945
View directory record Official record
Conditions
Non Hodgkin's Lymphoma
Interventions
clofarabine
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Sep 7, 2026, 2:42 PM EDT
Completed Not applicable Interventional Results available

Study Performance of The Plexur P™ Bone Void Filler Device in Patients Undergoing Iliac Crest Harvesting Procedures

NCT00837473
View directory record Official record
Conditions
Iliac Crest Harvesting Procedure-Bone Void Filler
Interventions
Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures
Device
Lead sponsor
Osteotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced Sep 7, 2026, 2:42 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation

NCT00275262
View directory record Official record
Conditions
Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mantle Cell Lymphoma
Interventions
Leuprolide acetate depot (LAD) 11.25 mg 3 Month, Matched placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
4
States / cities
St Louis, Missouri • New York, New York • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2010 · Synced Sep 7, 2026, 2:42 PM EDT
Recruiting Phase 4 Interventional

A Prospective, Randomized, Assessor-Blinded, Multicenter Study Comparing Avance Nerve Graft and Autograft for Functional Recovery Following Mixed and Motor Peripheral Nerve Reconstruction

NCT07657182
View directory record Official record
Conditions
Peripheral Nerve Injury, Peripheral Nerve Discontinuity, Mixed Peripheral Nerve Injury, Motor Peripheral Nerve Injury, Upper Extremity Nerve Injury
Interventions
Avance Nerve Graft, Sural nerve autograft
Biological · Procedure
Lead sponsor
Axogen Corporation
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 7, 2026, 2:42 PM EDT
Terminated Phase 2 Interventional

p53 Vaccine for Ovarian Cancer

NCT00001827
View directory record Official record
Conditions
Ovarian Neoplasm
Interventions
aldesleukin, incomplete Freund's adjuvant, p53 peptide vaccine, sargramostim, therapeutic autologous dendritic cells, in vitro-treated peripheral blood stem cell transplantation
Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 7, 2026, 2:42 PM EDT
Not yet recruiting Not applicable Interventional

Allograft vs. Autograft Nonunion

NCT07310082
View directory record Official record
Conditions
Nonunion Fracture
Interventions
Autograft, Allograft
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 7, 2026, 2:42 PM EDT
Recruiting Phase 4 Interventional

Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft

NCT06379724
View directory record Official record
Conditions
Burns, Skin Graft Complications
Interventions
Tranexamic acid, Thrombin JMI, skin graft
Drug · Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 7, 2026, 2:42 PM EDT